ArticleBiomedical optics express2019
Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings.
Article in Biomedical optics express, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- Article
- Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics.Sensors (Basel, Switzerland) · 2023Review
- Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy.Journal of Cancer · 2023Review
- Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.Frontiers in immunology · 2022Review
- On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy.Biosensors · 2021Review
- Immunosensing Based on Optical Fiber Technology: Recent Advances.Biosensors · 2021Review
- Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death ligand-1 (PD-L1) plays an important role in tumor evasion from the host immune system. The level of soluble PD-L1 (sPD-L1) in serum is closely related to tumor aggressiveness and outcomes. This study aimed to propose a localized surface Plasmon resonance (LSPR) biosensor based on excessively tilted fiber grating (ExTFG) coated with large-sized (∼160 nm) gold nanoshells for label-free and specific detection of sPD-L1. The experimental results showed that the limit of detection (LOD) of the immunosensor for sPD-L1 in buffer solutions was ∼1 pg/mL due to the enhanced LSPR effect resulting from the interaction between sPD-L1 molecules and anti-sPD-L1 monoclonal antibodies. The detection of sPD-L1 in complex serum media, such as fetal bovine serum, confirmed that the label-free immunosensor was extremely specific to sPD-L1 and could identify it at a concentration as low as 5 pg/mL. Therefore, it can be potentially applied in clinic for the fast and early diagnosis of cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.